In parallel, BsAbs targeting inhibitory checkpoints (e.g., PD-1, PD-L1, CTLA-4, LAG-3, and TIGIT) are being developed to reinvigorate exhausted immune cells through combined tumor-specific engagement.72 The gene discussed is CD274; the disease is neoplasm.